

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
17 June 2021 (17.06.2021)



(10) International Publication Number
WO 2021/113974 A1

(51) International Patent Classification:

C07K 16/46 (2006.01) A61P 7/02 (2006.01)
A61K 39/395 (2006.01) C07K 16/28 (2006.01)
A61K 39/44 (2006.01) C07K 19/00 (2006.01)
A61P 35/04 (2006.01)

(21) International Application Number:

PCT/CA2020/051699

(22) International Filing Date:

10 December 2020 (10.12.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/946,086 10 December 2019 (10.12.2019) US

(71) Applicant: CCOA THERAPEUTICS INC. [CA/CA];
Suite 414, 209 Victoria Street, Toronto, Ontario M5B 1T8
(CA).

(72) Inventor: NI, Heyu; 21 Rondeau Drive, North York, Ontario M2H 1R5 (CA).

(74) Agent: NORTON ROSE FULBRIGHT CANADA
S.E.N.C.R.L., S.R.L. / LLP; 2500, 1 Place Ville-Marie,
Montreal, Québec H3B 1R1 (CA).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:


- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(54) Title: HUMANIZED ANTI-GLYCOPROTEIN IB ALPHA (GPIBALPHA) ANTIBODIES

Figure 18



(57) Abstract: Multivalent anti-platelet glycoprotein I(b)alpha antibodies can cause severe side effects. The present disclosure provides humanized antibodies specifically recognizing glycoprotein I(b)alpha and lacking a Fc portion, therefore do not interact with Fc receptor. The humanized antibodies are capable of preventing platelet activation and aggregation, and reducing thrombus size / growth and prevent vessel occlusion. They can be also very useful to decrease platelet-tumor cell interaction and decrease tumor metastasis. At therapeutic doses, the humanized antibodies lack the ability to induce platelet activation, induce thrombocytopenia; and/or prolong bleeding time.

WO 2021/113974 A1